Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Beta + Fruquintinib +/- ICI in 1L RAS/BRAF WT mCRC
NCT07257653Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140, fruquintinib, sintilimab in colorectal cancer (CRC), sponsored by Zhejiang University. Started Oct 2025; status: recruiting.
02
Drugs
KL-140fruquintinibsintilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07257653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07257653.